Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Cash from Financing Activities (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Cash from Financing Activities for 7 consecutive years, with -$32.3 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 31734.31% to -$32.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$31.7 million through Dec 2025, down 237.12% year-over-year, with the annual reading at -$31.7 million for FY2025, 237.12% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was -$32.3 million at Pliant Therapeutics, down from $72000.0 in the prior quarter.
  • The five-year high for Cash from Financing Activities was $273.3 million in Q1 2023, with the low at -$32.3 million in Q4 2025.
  • Average Cash from Financing Activities over 5 years is $26.1 million, with a median of $498000.0 recorded in 2025.
  • The sharpest move saw Cash from Financing Activities soared 178744.44% in 2023, then crashed 31734.31% in 2025.
  • Over 5 years, Cash from Financing Activities stood at $516000.0 in 2021, then tumbled by 44.96% to $284000.0 in 2022, then dropped by 22.89% to $219000.0 in 2023, then plummeted by 53.42% to $102000.0 in 2024, then plummeted by 31734.31% to -$32.3 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at -$32.3 million, $72000.0, and $498000.0 for Q4 2025, Q3 2025, and Q1 2025 respectively.